Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Dec 8, 2025
Reporting period
Not applicable
Filed with the SEC
Dec 10, 2025
10% ownerIndirect holdingOption exercise
Context
Classification
option exercise
Code C — exercise or conversion of a derivative security
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001395064-25-000172
Filed / recorded
Dec 10, 2025, 2:19 AM UTC
Added to OQRO
Oct 7, 2026, 5:52 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Ovid Therapeutics Inc.
Issuer CIK
1636651
Ticker
OVID
Reporting person
TAKEDA PHARMACEUTICAL CO LTD
Relationship
10% owner
Security
Series A Convertible Preferred Stock
Table
Derivative (Table II)
Transaction date
Dec 8, 2025
Transaction code
C
Shares / units
1,250
Price per share
$0.00
Acquired / disposed
Disposed (D)
Shares owned after
0
Ownership form
Indirect — See Explanation of Responses
Amendment
No
Footnotes from the filing
Each share of Series A convertible preferred stock (the "Preferred Stock") of Ovid Therapeutics Inc. ("Ovid") was convertible into 1,000 shares of Ovid's common stock at any time at the election of TPUSA. On December 8, 2025, TPUSA elected to convert all 1,250 shares of Preferred Stock held by TPUSA.
The Preferred Stock had no expiration date.
The reportable securities are directly held by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"). TPUSA is a direct subsidiary of Takeda Pharmaceuticals International AG. Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As such, Takeda may be deemed to have indirect beneficial ownership of the securities held by TPUSA.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.